Table 9

Ovarian function suppression in premenopausal women

StudyTrial nameSettingPrimary outcomeMedian follow-up (months)DFS control (%)DFS gain (%)DFS HR*OS control (%)OS gain (%)OS HR*ESMO-MCBS V.1.1Reference
Exemestane+OFS vs Tam+OFSSOFT-TEXTAllDFS9682.84.00.77 (0.67–0.90)91.82.10.80 (0.66–0.96)C62 86
Tam vs Tam+OFS vs exemestane+OFSSOFTAllDFS Tam+OFS9678.94.30.76 (0.62–0.93)91.51.80.67 (0.48–0.92)C62 87
Tam vs Tam+OFS vs exemestane+OFSSOFTAllDFS E+OFS9678.97.0%0.65 (0.53–0.81)91.50.60.85 (0.62–1.15)NEB62 87
Tam vs Tam+OFS vs exemestane+OFSSOFTNo chemoDFS Tam+OFS9687.43.20.76 (0.52–1.12)1.60.74 (0.51–1.09)NEB62 87
Tam vs Tam+OFS vs exemestane+OFSSOFTNo chemoDFS E+OFS9687.45.20.58 (0.38–0.88)NEB62 87
Tam vs Tam+OFS vs exemestane+OFSSOFTPast- chemoDFS Tam+OFS9671.45.30.76 (0.60–0.97)85.14.30.59 (0.42–0.84)B62 87
Tam vs Tam+OFS vs exemestane+OFSSOFTPast- chemoDFS E+OFS9671.49.00.82 (0.64–1.07)85.12.10.79 (0.57–1.09)NEB62 87
Anastrozole+OFS vs Tam+OFSABCSG-12Premenopausal HR+DFS94.4NA1.08 (0.81–1.44)96.3−2.11.63 (1.05–2.52)NEB64 71 72
  • Chart blanks—relevant variables not available in manuscript.

  • *HR values in parentheses refer to 95% CI.

  • chemo, chemotherapy; DFS, disease-free survival; E, exemestane; ESMO-MCBS, The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale; OFS, ovarian function suppression; OS, overall survival; Tam, tamoxifen.